StockData
Alzamend Neuro, Inc. logo

Alzamend Neuro, Inc. (ALZN) stock

ALZNNasdaqPharmaceutical PreparationsFiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 10, 2026Score 4/30
$1.04−0.09 (-7.96%)

Close on Nov 18, 2026Market cap $5.02MP/E –Yield –

Alzamend Neuro operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Alzamend Neuro's operating income for the twelve months ending Jul 31, 2026 was -$9.09M. For fiscal 2026 it was -$8.77M. The highest annual figure on record is -$4.42M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2026Apr 30, 2026-$8.77M–
FY2025Apr 30, 2025-$4.50M–
FY2024Apr 30, 2024-$9.94M–
FY2023Apr 30, 2023-$14.87M–
FY2022Apr 30, 2022-$12.32M–
FY2021Apr 30, 2021-$4.95M–
FY2020Apr 30, 2020-$4.42M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jul 31, 2026-$3.03M–
Q4 FY2026CQ1 2026Apr 30, 2026-$2.87M–
Q3 FY2026CQ4 2025Jan 31, 2026-$2.20M–
Q2 FY2026CQ3 2025Oct 31, 2025-$998.11K–
Q1 FY2026CQ2 2025Jul 31, 2025-$2.70M–
Q1 FY2025CQ2 2024Jul 31, 2024-$962.41K–
Q4 FY2024CQ1 2024Apr 30, 2024-$850.06K–
Q3 FY2024CQ4 2023Jan 31, 2024-$2.66M–
Q2 FY2024CQ3 2023Oct 31, 2023-$2.90M–
Q1 FY2024CQ2 2023Jul 31, 2023-$3.53M–
Q4 FY2023CQ1 2023Apr 30, 2023-$3.31M–
Q3 FY2023CQ4 2022Jan 31, 2023-$5.42M–
Q2 FY2023CQ3 2022Oct 31, 2022-$3.11M–
Q1 FY2023CQ2 2022Jul 31, 2022-$3.04M–
Q4 FY2022CQ1 2022Apr 30, 2022-$3.87M–
Q3 FY2022CQ4 2021Jan 31, 2022-$2.56M–
Q2 FY2022CQ3 2021Oct 31, 2021-$3.58M–
Q1 FY2022CQ2 2021Jul 31, 2021-$2.31M–
Q4 FY2021CQ1 2021Apr 30, 2021-$1.22M–
Q3 FY2021CQ4 2020Jan 31, 2021-$1.12M–
Q2 FY2021CQ3 2020Oct 31, 2020-$1.30M–
Q1 FY2021CQ2 2020Jul 31, 2020-$1.32M–

More Alzamend Neuro figures

See a number that looks wrong?